[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100578116":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":27,"locations":35,"responsibleParty":49,"collaborators":51,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":10,"eligibilityCriteria":61,"healthyVolunteers":57,"sex":62,"minAge":63,"maxAge":10,"enrollmentInfo":64,"targetDuration":10,"studyType":67,"phases":10,"briefSummary":68,"conditions":69,"keywords":72,"overallStatus":77,"whyStopped":10,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Charles University, Czech Republic","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients with pancreatic ductal adenocarcinoma scheduled for surgery",null,"Both male and female patients of all age diagnosed with pancreatic ductal adenocarcinoma and indicated for surgical treatment by multidisciplinary tumor board. Patients with and without previously completed chemotherapy will be included.",[13],"Other: Intravenously administered secretin",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"Intravenously administered secretin","16 micrograms of liquid secretin will be one-time intravenously administered to patients with PDAC during the first hour of surgery. Four peripheral blood samples will then be collected. Plasmatic levels of ctDNA will be measured. Plasmatic levels of biomarkers such as mRNA, miRNA, siRNA, exoRNA, S100 proteins and amino acids, isolated from the same blood samples, will be measured and analyzed in correlation to tumor volumometry, survival rate etc. in specific intervals during follow-ups.",[9],[20,24],{"name":21,"affiliation":22,"role":23},"Jan Bureš, prof., MD, CSc., FCMA","Military University Hospital in Prague","STUDY_DIRECTOR",{"name":25,"affiliation":22,"role":26},"Kristýna Pončáková, MD","PRINCIPAL_INVESTIGATOR",[28,32],{"name":25,"role":29,"phone":30,"phoneExt":10,"email":31},"CONTACT","+420720413031","poncakova.kristyna@seznam.cz",{"name":33,"role":29,"phone":10,"phoneExt":10,"email":34},"Radek Pohnán, plk. doc., MD, Ph.D.","pohnarad@uvn.cz",[36],{"facility":37,"status":10,"city":38,"state":10,"zip":39,"country":40,"countryCode":10,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Department of Surgery, Military University Hospital in Prague","Prague","16902","Czechia",{"type":42,"coordinates":43},"Point",[44,45],14.42076,50.08804,{"lat":45,"lon":44},[48],{"name":33,"role":29,"phone":10,"phoneExt":10,"email":34},{"type":50,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[52],{"name":53,"class":54},"Military University Hospital in Prague, Czech Republic","UNKNOWN","100578116","the-influence-of-secretin-stimulated-pancreatic-secretion-on-ctdna-expression-in-patients-with-pancreatic-ductal-adenocarcinoma-the-role-of-biomarkers-in-determining-the-prognosis-of-pancreatic-ductal-adenocarcinoma-100578116",false,"NCT06807112","The Influence of Secretin Stimulated Pancreatic Secretion on ctDNA Expression in Patients With Pancreatic Ductal Adenocarcinoma: The Role of Biomarkers in Determining the Prognosis of Pancreatic Ductal Adenocarcinoma","The Influence of Secretin Stimulated Pancreatic Secretion on Circulating Tumor DNA Expression in Patients With Pancreatic Ductal Adenocarcinoma: The Role of Biomarkers in Determining the Prognosis of Pancreatic Ductal Adenocarcinoma","Inclusion Criteria:\n\n* patients diagnosed with pancreatic ductal adenocarcinoma\n* patients indicated for surgery by multidisciplinary tumor board\n* patients without previously administered chemotherapy\n* patients with previously administered chemotherapy\n\nExclusion Criteria:\n\n* patients diagnosed with pancreatic ductal adenocarcinoma, at the time indicated for different than surgical therapy","ALL","18 Years",{"count":65,"type":66},39,"ESTIMATED","OBSERVATIONAL","The goal of this study is to assess the influence of pancreatic secretion stimulation by intravenously administered secretin on circulating tumor DNA in patients with pancreatic ductal adenocarcinoma. Additional aim of the study is to analyse a role of specific biomarkers in determining the prognosis of this disease. The main question o answer is:\n\nDoes intravenous secretin administration potentiate the release of circulating tumor DNA in patients with pancreatis ductal adenocarcinoma?\n\nAdditional question is:\n\nIs there a biomarker specific and sensitive enough to help to predict the prognosis and the at the time status of the disease?\n\nParticipants scheduled for surgical treament due to pancreatic ductal adenocarcinoma will be included and stimulated with intravenously administered secretin, their peripheral blood samples will then be analyzed for ctDNA levels.",[70,71],"Pancreatic Adenocarcinoma","Pancreatic Cancer",[73,74,75,76],"Secretin","Panreatic ductal adenocarcinoma","Biomarker","Circulating tumor DNA","NOT_YET_RECRUITING","2025-02-03",{"date":80,"type":81},"2025-02-04","ACTUAL",{"date":83,"type":66},"2025-02-09",{"date":85,"type":66},"2027-02-01",{"name":5,"class":6},1]